Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics von Hoshino-Yoshino, Azusa, Kato, Motohiro, Nakano, Kohnosuke, Ishigai, Masaki, Kudo, Toshiyuki, Ito, Kiyomi

Volltext

Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans - toxicological implications von Shindoh, Hidetoshi, Nakano, Kohnosuke, Yoshida, Takemi, Ishigai, Masaki

Volltext

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers von Ono, Naomi, Yamazaki, Toshikazu, Nakanishi, Yoshito, Fujii, Toshihiko, Sakata, Kiyoaki, Tachibana, Yukako, Suda, Atsushi, Hada, Kihito, Miura, Takaaki, Sato, Shigeo, Saitoh, Ryoichi, Nakano, Kohnosuke, Tsukuda, Takuo, Mio, Toshiyuki, Ishii, Nobuya, Kondoh, Osamu, Aoki, Yuko

Volltext

Bevacizumab improves the delivery and efficacy of paclitaxel von Yanagisawa, Mieko, Yorozu, Keigo, Kurasawa, Mitsue, Nakano, Kohnosuke, Furugaki, Koh, Yamashita, Yoriko, Mori, Kazushige, Fujimoto-Ouchi, Kaori

Volltext

Bevacizumab improves the delivery and efficacy of paclitaxel von Yanagisawa, Mieko, Yorozu, Keigo, Kurasawa, Mitsue, Nakano, Kohnosuke, Furugaki, Koh, Yamashita, Yoriko, Mori, Kazushige, Fujimoto-Ouchi, Kaori

Volltext